Wuhan Keqian BiologyLtd Future Growth
Future criteria checks 4/6
Wuhan Keqian BiologyLtd is forecast to grow earnings and revenue by 25.1% and 21% per annum respectively. EPS is expected to grow by 25.1% per annum. Return on equity is forecast to be 11.8% in 3 years.
Key information
25.1%
Earnings growth rate
25.1%
EPS growth rate
| Pharmaceuticals earnings growth | 18.7% |
| Revenue growth rate | 21.0% |
| Future return on equity | 11.8% |
| Analyst coverage | Good |
| Last updated | 04 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,545 | 601 | 460 | 643 | 6 |
| 12/31/2025 | 1,341 | 531 | 399 | 572 | 7 |
| 12/31/2024 | 1,142 | 445 | 457 | 490 | 7 |
| 9/30/2024 | 902 | 299 | 289 | 365 | N/A |
| 6/30/2024 | 933 | 309 | 385 | 478 | N/A |
| 3/31/2024 | 989 | 348 | 398 | 493 | N/A |
| 12/31/2023 | 1,064 | 396 | 434 | 538 | N/A |
| 9/30/2023 | 1,142 | 484 | 447 | 538 | N/A |
| 6/30/2023 | 1,139 | 490 | 374 | 460 | N/A |
| 3/31/2023 | 1,078 | 454 | 394 | 495 | N/A |
| 12/31/2022 | 1,001 | 410 | 321 | 424 | N/A |
| 9/30/2022 | 1,014 | 468 | 240 | 389 | N/A |
| 6/30/2022 | 952 | 444 | 238 | 438 | N/A |
| 3/31/2022 | 987 | 493 | 109 | 389 | N/A |
| 12/31/2021 | 1,103 | 571 | 157 | 531 | N/A |
| 9/30/2021 | 1,015 | 514 | 185 | 515 | N/A |
| 6/30/2021 | 1,033 | 551 | 261 | 562 | N/A |
| 3/31/2021 | 987 | 524 | 336 | 546 | N/A |
| 12/31/2020 | 843 | 448 | 289 | 400 | N/A |
| 9/30/2020 | 723 | 371 | 260 | 387 | N/A |
| 6/30/2020 | 576 | 271 | 80 | 194 | N/A |
| 3/31/2020 | 539 | 258 | 91 | 220 | N/A |
| 12/31/2019 | 508 | 243 | 17 | 155 | N/A |
| 12/31/2018 | 735 | 389 | 320 | 352 | N/A |
| 12/31/2017 | 633 | 320 | N/A | 338 | N/A |
| 12/31/2016 | 390 | 186 | N/A | 221 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688526's forecast earnings growth (25.1% per year) is above the savings rate (2.8%).
Earnings vs Market: 688526's earnings (25.1% per year) are forecast to grow slower than the CN market (26.3% per year).
High Growth Earnings: 688526's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 688526's revenue (21% per year) is forecast to grow faster than the CN market (13.9% per year).
High Growth Revenue: 688526's revenue (21% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688526's Return on Equity is forecast to be low in 3 years time (11.8%).